TY - JOUR
T1 - Cancer‐induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin
AU - ULTRA‐J group
AU - Hashimoto, Mamoru
AU - Fukiage, Ken
AU - Taniguchi, Kosei
AU - Minami, Takafumi
AU - Yanagisawa, Takafumi
AU - Fukuokaya, Wataru
AU - Maenosono, Ryoichi
AU - Yoshikawa, Yuki
AU - Tsujino, Takuya
AU - Saruta, Masanobu
AU - Takahara, Kiyoshi
AU - Hirasawa, Yosuke
AU - Hashimoto, Takeshi
AU - Ohno, Yoshio
AU - Kimura, Takahiro
AU - Shiroki, Ryoichi
AU - Fujita, Kazutoshi
N1 - Publisher Copyright:
©2025 The Author(s).
PY - 2025/5
Y1 - 2025/5
N2 - Background/Aim: Cancer‑induced pain (CIP) exacerbates patient’s quality of life. However, it is unknown whether CIP is associated with survival in urothelial carcinoma (UC) patients treated with enfortumab vedotin (EV). This study retrospectively investigated the prognostic significance of CIP in EV‑treated UC patients. Patients and Methods: We analyzed clinical data from patients with locally advanced or metastatic UC who received EV treatment, assessing various factors such as age, metastasis site, ECOG Performance Status (PS), and CIP status prior to treatment. CIP was determined based on clinical records cancer‑related pain or the use of analgesics for pain management. Results: A total of 114 patients (78 males and 36 females) were included in the study. The group with CIP included significantly higher number of patients with bone metastasis. Progression‑free survival of the patients with CIP was not significantly different from those without CIP. However, the patients with CIP showed worse overall survival (OS) than those without CIP. Cox proportional regression analysis showed that CIP, liver metastasis, and ECOG PS were significant predictors of poorer OS. Conclusion: CIP before the treatment of EV was a significant predictor of reduced OS in patients with UC. Early management of CIP or initiation of EV therapy before CIP development may improve survival outcomes.
AB - Background/Aim: Cancer‑induced pain (CIP) exacerbates patient’s quality of life. However, it is unknown whether CIP is associated with survival in urothelial carcinoma (UC) patients treated with enfortumab vedotin (EV). This study retrospectively investigated the prognostic significance of CIP in EV‑treated UC patients. Patients and Methods: We analyzed clinical data from patients with locally advanced or metastatic UC who received EV treatment, assessing various factors such as age, metastasis site, ECOG Performance Status (PS), and CIP status prior to treatment. CIP was determined based on clinical records cancer‑related pain or the use of analgesics for pain management. Results: A total of 114 patients (78 males and 36 females) were included in the study. The group with CIP included significantly higher number of patients with bone metastasis. Progression‑free survival of the patients with CIP was not significantly different from those without CIP. However, the patients with CIP showed worse overall survival (OS) than those without CIP. Cox proportional regression analysis showed that CIP, liver metastasis, and ECOG PS were significant predictors of poorer OS. Conclusion: CIP before the treatment of EV was a significant predictor of reduced OS in patients with UC. Early management of CIP or initiation of EV therapy before CIP development may improve survival outcomes.
KW - Cancer‑induced pain
KW - Enfortumab Vedotin
KW - urothelial carcinoma
UR - https://www.scopus.com/pages/publications/105004240382
UR - https://www.scopus.com/inward/citedby.url?scp=105004240382&partnerID=8YFLogxK
U2 - 10.21873/invivo.13953
DO - 10.21873/invivo.13953
M3 - Article
C2 - 40295006
AN - SCOPUS:105004240382
SN - 0258-851X
VL - 39
SP - 1533
EP - 1539
JO - In Vivo
JF - In Vivo
IS - 3
ER -
